Nuvectra is permanently ending its operations. This decision is a result of the sale of our intellectual property and certain assets to Cirtec Medical Corporation and travel restrictions on our representatives as a result of the ongoing coronavirus (COVID-19) pandemic.

  • We have ceased all field patient support, product warranty replacements and treatment activities, effective immediately.
  • We will continue to provide patient support by phone through confirmation of our Plan of Reorganization by the Bankruptcy Court, which may be as early as April 17, 2020. Thereafter, those services will not be available.
  • We cannot provide adjustments to therapy or reprogramming.
  • MRIs can no longer be cleared and the conditions for MRIs cannot be met.
  • We are no longer offering patient education or troubleshooting programs.
  • Programmer or equipment replacements are no longer available – it is vital that patients keep their current products charged at this time.
We cannot make specific recommendations regarding patient medical care, and we urge patients to consult their physician if they have questions about keeping or removing their device.

Nuvectra®  Presents Algovita® SCS.

Therapy for Chronic Pain.

nuvectra

Discover more, tell us who you are

More information on Chapter 11 Bankruptcy Process


Nuvectra™ Presents Algovita® SCS.

Therapy for Chronic Pain.

On November 12, 2019, Nuvectra voluntarily commenced a court-supervised process under Chapter 11 of the U.S. Bankruptcy Code to provide the Company the time and flexibility to continue its review of a range of strategic options to maximize value and address its financial obligations.

Information for patients about this process can be found here.

Information for physicians about this process can be found here.